Low Molecular Weight Aurin Compounds for Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions involving aberrant complement activation, such as age-related macular degeneration, rheumatoid arthritis, and paroxysmal nocturnal hemoglobinemia, are inadequate as they either fail to block C3 convertase activity or cannot cross the blood-brain barrier, leading to self-damage from membrane attack complex formation.
Innovation Solution
The use of low molecular weight components of the aurin tricarboxylic acid synthetic complex (ATAC), specifically aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), and aurin hexacarboxylic acid (AHA), which selectively block C3 convertase and membrane attack complex formation, allowing for oral administration and crossing the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If eculizumab is used to block C5 conversion, then membrane attack complex formation is inhibited, but C3 convertase activity remains active causing ongoing hemolysis
Solution Approach 1:
The invention segments the complement inhibition function into two distinct mechanisms: C3 convertase blocking (via Factor D binding) and membrane attack complex blocking (via C9 binding). This segmentation allows simultaneous inhibition of both harmful functions without the trade-off present in eculizumab, which only blocks C5 conversion and leaves C3 convertase activity unchecked.
Solution Approach 2:
The patent uses intermediary molecules that bind to specific complement components (Factor D for C3 convertase blocking, C9 for membrane attack complex blocking). These intermediaries act as selective inhibitors that can simultaneously target multiple complement activation steps without requiring high molecular weight antibodies, thus resolving the contradiction between blocking MAC formation and maintaining C3 convertase inhibition.
2Reliability
If high molecular weight antibodies like eculizumab are used, then complement activation is blocked, but the drug cannot cross the blood-brain barrier for CNS disorders
Solution Approach 1:
The invention fundamentally changes the molecular weight parameter of the complement inhibitors, using low molecular weight compounds (under 1 kDa) instead of high molecular weight antibodies. This parameter change enables the drugs to cross the blood-brain barrier while maintaining complement inhibition effectiveness through nanomolar concentrations achieved via oral administration.
Solution Approach 2:
The patent replaces the mechanical delivery system of intravenous antibodies with oral administration of low molecular weight compounds. This substitution allows the inhibitors to be absorbed through the gastrointestinal tract and cross the blood-brain barrier, providing versatility for both systemic and CNS disorders without relying on injection-based delivery.
3Ease of operation
If orally effective agents are used, then administration convenience is improved, but sufficient complement inhibition was not achieved
Solution Approach 1:
The invention changes the concentration parameter by achieving nanomolar levels of complement inhibition through oral administration. The low molecular weight nature of the compounds enables sufficient bioavailability and brain penetration at these low concentrations, proving that oral administration can achieve reliable complement inhibition without requiring high doses.
4Object-affected harmful factors
If C3 convertase is blocked, then alternative pathway activation is prevented, but classical pathway opsonization may be compromised
Solution Approach 1:
The invention applies local quality by differentiating the inhibition mechanism: Factor D binding specifically blocks C3 convertase activity without interfering with C1q-mediated classical pathway opsonization. This selective local inhibition allows the system to maintain beneficial opsonization functions while preventing harmful alternative pathway activation and membrane attack complex formation.
Data Source
AI summary
A method of treating age-related macular degeneration. The method includes the step of administering orally or parenterally an effective amount of aurin tricarboxylic acid, aurin quadracarboxylic acid, and/or aurin hexacarboxylic acid, wherein the method excludes administration of components of aurin tricarboxylic acid complex of greater than or equal to 1 kilodalton in molecular weight.